Every story in this section, newest first — page 45 of 373.
SCYNEXIS (NASDAQ:SCYX) secured a contract with the Biomedical Advanced Research and Development Authority to support development of SCY-247, with potential funding of up to approximately $214 million.
Valley National Bancorp (NASDAQ:VLY) agreed to acquire Bluevine for approximately $340 million in a cash-and-stock transaction expected to include about 75% cash and 25% Valley common stock.
Soluna Holdings (NASDAQ:SLNH) amended its agreement with Bitdeer Technologies Group (NASDAQ:BTDR) subsidiary Dory Creek to expand Bitcoin mining operations at Soluna’s Project Kati 1 in South Texas.
TOYO (NASDAQ:TOYO) signed binding U.S. solar module supply agreements worth approximately $240 million with multiple U.S. customers since mid-June 2026.
Arvinas (NASDAQ:ARVN) dosed the first participant in a Phase 1/2 trial of ARV-6723, an investigational oral immuno-oncology candidate designed to degrade HPK1 in adults with advanced solid tumors.
Cosmos Health (NASDAQ:COSM) reported more than $20 million in implied revenue from Cana Laboratories’ contract manufacturing pipeline, based on management estimates over the expected duration of agreements.
Foresight Autonomous Holdings (NASDAQ:FRSX) signed a non-binding term sheet to acquire a 50.01% stake in a company advancing two data center projects in Poland.
TOYO (NASDAQ:TOYO) said it expects positive EBITDA for the second half of 2026 while withholding specific financial guidance due to ongoing U.S. trade and regulatory uncertainty.
AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.
Maris-Tech (NASDAQ:MTEK) received a US$10 million order to develop and supply video systems for next-generation manned airborne platforms under a multi-year project with Magam Safety.
TransDigm Group (NYSE:TDG) completed its acquisition of Prince & Izant for approximately $1.066 billion in cash, including certain tax benefits.
Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.
Ramaco Resources (NASDAQ:METC) secured a $30 million court judgment for its subsidiary Ramaco Resources in an insurance coverage dispute against Chubb subsidiaries Federal Insurance Company and ACE American Insurance Company.
Palatin Technologies (NASDAQ:PTN) reported fiscal 2026 collaboration and license revenue of $13.2 million, compared with zero revenue in fiscal 2025.
Kandi Technologies (NASDAQ:KNDI) secured a second heavy-truck battery swap station equipment order through its China Battery Exchange subsidiary from QIJI Energy, a subsidiary of CATL.
AN2 Therapeutics (NASDAQ:ANTX) received an extension of funding from the Gates Foundation to support its tuberculosis research collaboration with GSK focused on boron-based leucyl-tRNA synthetase inhibitors.
Eton Pharmaceuticals (NASDAQ:ETON) launched IMPAVIDO (miltefosine) capsules in the United States under exclusive U.S. commercialization rights for the treatment of certain forms of leishmaniasis.
Armlogi Holding (NASDAQ:BTOC) reported fiscal 2026 revenue of $185.8 million for the year ended June 30, 2026, compared with $190.4 million in fiscal 2025.
Brixmor Property Group (NYSE:BRX) and Everview Partners agreed to acquire Slate Grocery REIT in a $2.34 billion transaction involving 115 grocery-anchored centers.
Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.
Eli Lilly (NYSE:LLY) launched the Change the Course Commitment, an initiative aimed at increasing access to its diabetes and obesity medicines in resource-limited settings before 2040.
Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.
Codexis (NASDAQ:CDXS) signed an agreement with an unnamed siRNA drug developer to explore stereo-defined fragment synthesis using its ECO Synthesis platform.
National Healthcare Properties (NYSE:NHP) agreed to sell 40 outpatient medical facilities for approximately $531 million, with closing expected in the fourth quarter of 2026.
